Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

NCT04831320 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Head-and-neck Squamous-cell Carcinoma

Interventions

DRUG: nab-paclitaxel
DRUG: Nivolumab

Sponsor

Washington University School of Medicine

Collaborators

[object Object]